<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547661</url>
  </required_header>
  <id_info>
    <org_study_id>ID 2017-02186</org_study_id>
    <secondary_id>325130_170117</secondary_id>
    <nct_id>NCT03547661</nct_id>
  </id_info>
  <brief_title>Open-Label Placebo Treatment of Women With Premenstrual Syndrome</brief_title>
  <acronym>OLPPMS_1</acronym>
  <official_title>Open-Label Placebo Treatment of Women With Premenstrual Syndrome: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jens Gaab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of an open-label placebo intervention on
      premenstrual syndrome (PMS) complaints. Women who suffer from moderate to severe PMS will be
      randomly allocated to three groups: to a treatment as usual group, an open-label placebo
      group, and an integrative open-label placebo group. Participants of all groups will conclude
      a prospective PMS screening for one menstrual cycle. Thereafter, participants of both
      intervention groups will obtain an openly administered placebo intervention for six weeks.
      Participants of the treatment as usual group will have the chance to obtain the same
      open-label placebo intervention after study conduct. Diverse measures will be assessed by
      means of a PMS symptom diary and questionnaires.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent evidence suggests that in certain clinical conditions - such as chronic low-back pain,
      migraine, irritable bowel syndrome, attention deficit hyperactivity disorder, and rhinitis -
      placebos improve clinical outcomes even without deception. Premenstrual syndrome (PMS) is
      defined as clinically significant symptoms, comprising at least one emotional or physical
      symptom in the premenstrual phase of the menstrual cycle and which cause substantial distress
      or functional impairment. To date, there exists no study examining open-label placebo
      responses on PMS. However, PMS seems to be considerably susceptible to placebo effects: The
      Royal College of Obstetricians and Gynaecologists alerts to substantial placebo responses in
      randomized-controlled PMS trials and studies showed considerable placebo effects on PMS
      without any specific effect for the medication under examination. Furthermore, a myriad of
      distinctive therapies is described for PMS (including pharmacological and phytopharmaceutical
      drugs as well as complementary non-pharmacological interventions), yet partially mixed
      evidence is reported. Besides being considered as placebogenic, PMS symptoms are timely
      well-defined and delimited which further makes this condition attractive for an investigation
      of open-label placebo responses, as a possible amelioration can be measured in a delimited
      time frame. To sum up, a randomized controlled trial of an open-label placebo treatment of
      women with PMS allows to investigate ways to harness placebo effects ethically in clinical
      practice for syndromes with somatic and psychologically described characteristics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PMS symptom intensity assessed by a PMS symptom diary sub sum score</measure>
    <time_frame>Continuous measurement, starting from day 1 of the menstrual cycle (length of each cycle is on average 28 days) until the individual last day of the third menstrual cycle of each participant (assessment across three menstrual cycles in total)</time_frame>
    <description>Symptom intensity will be assessed by an intensity sub scale of the PMS symptom diary. Intensity will be rated by means of a six-level Likert scale, whereat 1 is the lowest rating of symptom intensity and 6 the highest.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PMS symptom interference assessed by a PMS symptom diary sub sum score</measure>
    <time_frame>Continuous measurement, starting from day 1 of the menstrual cycle (length of each cycle is on average 28 days) until the individual last day of the third menstrual cycle of each participant (assessment across three menstrual cycles in total)</time_frame>
    <description>Symptom interference will be assessed by an interference sub scale of the PMS symptom diary. Interference will be rated by means of a six-level Likert scale, whereat 1 is the lowest rating of interference and 6 the highest.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Premenstrual Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The treatment as usual (TAU) group will control for regression to the mean, spontaneous remission, natural course of disease, and the participants-provider interaction. Participants of the TAU group are allowed to continue their usual medication intake, given they are already on a stable dose (at least 30 days of intake) and the medication is not listed in the exclusion criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Integrative Open-Label Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention will encompass an integrative administration of &quot;P-Dragees rosa Lichtenstein&quot;, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.
All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The intervention will encompass an administration of &quot;P-Dragees rosa Lichtenstein&quot;, which are pink placebo dragées without any active ingredient. Each dragée contents the following substances: lactose monohydrate; magnesium stearate (Ph. Eur.); microcrystalline cellulose; highly dispersed silicon dioxide; white clay, macrogol glycerolhydroxy stearate (Ph. Eur.); Arabic gum; montanglycol wax; povidone (K 25); talcum; titanium dioxide (E 171); erythrosine; aluminium salt (E 127); calcium carbonate; sucrose; glucose syrup; maize starch; macrogol 6000.
All participants will be informed that the administered dragées are placebo dragées and participants will be instructed to take two dragées a day for six weeks. (Amendment regarding dosage since 08/18)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>P-Dragees rosa Lichtenstein</intervention_name>
    <description>Placebo dragées</description>
    <arm_group_label>Integrative Open-Label Placebo</arm_group_label>
    <arm_group_label>Open-Label Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe PMS

          -  Between 18 and 45 years of age

          -  A regular menstrual cycle, i.e., max. +/- 3 days of difference of cycle range

          -  Menstrual cycle range not longer than 31 or shorter than 24 days

          -  Participants have a general practioner or gynaecologist to consult

          -  At least one premenstrual symptom causes the desire for a PMS treatment

        Exclusion Criteria:

          -  Brest feeding at the moment or during the last three months

          -  Pregnancy

          -  Failing menstruation onset in the course of two consecutive menstrual cycles

          -  An essential mental or somatic disease

          -  Drug or massive alcohol intake or of other psychoactive substances

          -  Uptake of a new medication within the last 30 days

          -  Menopause, premenopausal strain or amenorrhoea

          -  Allergy of one of the ingredients of the placebo dragées (P-Dragees rosa Lichtenstein)

          -  Women who are surgically sterilised, hysterectomised, or ovariectomised

          -  BMI above 30

          -  Actual or recent participation in psychotherapy due to premenstrual symptoms

          -  Parallel participation in another study with investigational drugs or participation in
             another PMS study within the last three months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Gaab, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Basel, Faculty of Psychology, Division for Clinical Psychology and Psychotherapy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antje Frey Nascimento, MSc</last_name>
    <phone>+41 61 207 05 98</phone>
    <email>antje.freynascimento@unibas.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cosima Locher, Dr. phil.</last_name>
    <phone>+41 061 207 03 85</phone>
    <email>cosima.locher@unibas.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Basel, Faculty of Psychology, Division of Clinical Psychology and Psychotherapy</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4055</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antje Frey Nascimento, MSc</last_name>
    </contact>
    <contact_backup>
      <last_name>Cosima Locher, Dr. phil.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jens Gaab, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Carvalho C, Caetano JM, Cunha L, Rebouta P, Kaptchuk TJ, Kirsch I. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016 Dec;157(12):2766-2772. Erratum in: Pain. 2017 Feb;158(2):365.</citation>
    <PMID>27755279</PMID>
  </reference>
  <reference>
    <citation>Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, Kaptchuk TJ, Burstein R. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med. 2014 Jan 8;6(218):218ra5. doi: 10.1126/scitranslmed.3006175.</citation>
    <PMID>24401940</PMID>
  </reference>
  <reference>
    <citation>Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkotou E, Singer JP, Kowalczykowski M, Miller FG, Kirsch I, Lembo AJ. Placebos without deception: a randomized controlled trial in irritable bowel syndrome. PLoS One. 2010 Dec 22;5(12):e15591. doi: 10.1371/journal.pone.0015591.</citation>
    <PMID>21203519</PMID>
  </reference>
  <reference>
    <citation>Maharaj S, Trevino K. A Comprehensive Review of Treatment Options for Premenstrual Syndrome and Premenstrual Dysphoric Disorder. J Psychiatr Pract. 2015 Sep;21(5):334-50. doi: 10.1097/PRA.0000000000000099. Review.</citation>
    <PMID>26352222</PMID>
  </reference>
  <reference>
    <citation>O'Brien, P. S., Rapkin, A., &amp; Schmidt, P. J. (2007). The premenstrual syndromes: PMS and PMDD: CRC Press.</citation>
  </reference>
  <reference>
    <citation>Sampson GA. Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br J Psychiatry. 1979 Sep;135:209-15.</citation>
    <PMID>385093</PMID>
  </reference>
  <reference>
    <citation>Sandler AD, Bodfish JW. Open-label use of placebos in the treatment of ADHD: a pilot study. Child Care Health Dev. 2008 Jan;34(1):104-10. doi: 10.1111/j.1365-2214.2007.00797.x.</citation>
    <PMID>18171451</PMID>
  </reference>
  <reference>
    <citation>Schaefer M, Harke R, Denke C. Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial. Psychother Psychosom. 2016;85(6):373-374. Epub 2016 Oct 15.</citation>
    <PMID>27744433</PMID>
  </reference>
  <reference>
    <citation>Van Ree JM, Schagen Van Leeuwen JH, Koppeschaar HP, Te Velde ER. Unexpected placebo response in premenstrual dysphoric disorder: implication of endogenous opioids. Psychopharmacology (Berl). 2005 Oct;182(2):318-9. Epub 2005 Oct 19.</citation>
    <PMID>16001107</PMID>
  </reference>
  <reference>
    <citation>Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 5;371(9619):1200-10. doi: 10.1016/S0140-6736(08)60527-9.</citation>
    <PMID>18395582</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Jens Gaab</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Premenstrual Syndrome</keyword>
  <keyword>Open-Label Placebo Effect</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

